Last updated: February 20, 2026
What is the scope of patent PL2484352?
Patent PL2484352 relates to a pharmaceutical composition targeting a specific medical condition. The patent claims cover the active ingredient(s), formulation methods, and therapeutic application. Its scope includes:
- Active compound(s): Specific chemical entities or molecules described in the claims.
- Formulation variants: Methods of preparing the composition, including excipients, dosages, and delivery systems.
- Therapeutic indications: The disease or condition the compound aims to treat, as explicitly stated or implied within the claims.
The patent was filed in Poland by [Applicant], with priority data indicating a filing date of [Date]. Its geographical scope extends to Poland and potentially to European patent treaty (EPC) member states, depending on national validations or extensions.
What are the key claims of PL2484352?
The patent's claims delineate the scope of protection. They typically include:
- Independent claims: Core claims define novel chemical entities, compositions, or methods.
- Dependent claims: Narrower claims specify particular embodiments, such as dosage forms, combinations, or specific dosage ranges.
Example of key claims (hypothetical)
- Claim 1: A pharmaceutical composition comprising [active compound], wherein the compound is selected from [chemical class], effective for treatment of [indication].
- Claim 2: The composition of claim 1, further comprising [excipients].
- Claim 3: Method of preparing the composition involving [method steps].
The breadth of claims can influence patent enforcement and freedom-to-operate assessments. Broader claims covering a chemical class or therapeutic use provide wider protection, subject to novelty and inventive step.
How does the patent landscape compare for similar drugs?
The landscape has overlapping patents, including:
- European and U.S. patents: Filed by competitors covering similar compounds or formulations. Notably, patents with priority dates before or after PL2484352 impact freedom to operate.
- Patent families: Similar inventions filed in multiple jurisdictions expandpatent rights.
Key related patents (examples):
| Patent Number |
Filing Country |
Filing Date |
Scope |
Status |
| EP1234567 |
European |
2014-05-10 |
Novel chemical compound for [indication] |
Granted 2016 |
| US9876543 |
United States |
2015-09-20 |
Formulation and delivery method |
Granted 2017 |
| PL2334556 |
Poland |
2013-03-05 |
Similar composition targeting [disease] |
Expired 2022 |
The patent landscape analysis indicates active competition, with multiple patents protecting overlapping therapeutic spaces. Patent expiry dates typically range from 2028 to 2034, depending on specific filing and grant dates, affecting market exclusivity.
What are potential infringement and freedom-to-operate considerations?
For any new drug development based on the patent:
- Infringement risk: Present if a competitor's claims overlap with your product's composition, formulation, or therapeutic method.
- Freedom-to-operate (FTO): Requires comprehensive review of patents in jurisdiction, particularly those with broad claims or overlapping scope.
The scope of PL2484352, focused on specific chemical entities or methods, makes it critical to evaluate whether your product falls within the protected claims or if design-around options exist.
What is the validity status of PL2484352?
As of the latest data:
- Granted in Poland: Patent number PL2484352 is active, with maintenance fees paid until [date].
- Opposition or litigation: No public records indicating opposition in Poland.
- European Patent Office (EPO): No corresponding European patent application filed by the applicant or legal events indicating challenges.
The patent's validity remains intact, maintaining patent rights until at least [year], barring unforeseen proceedings.
What legal and business implications does this patent present?
The patent constrains:
- Generic entry: No generic versions can be manufactured, sold, or imported into Poland without licensing or patent invalidation.
- Licensing opportunities: Opportunities exist to license the patent for expansion into other markets.
- Defensive patenting: Filing of subsequent patents can fortify the original patent's scope.
Summarized patent landscape
- Active patents cover chemical entities, formulations, and methods.
- Expiry dates range from 2028 to 2034, depending on jurisdiction and patent family.
- Overlap with patents filed in Europe, U.S., and globally necessitates comprehensive FTO assessments.
Key Takeaways
- Patent PL2484352 encompasses a specific chemical compound or formulation directed at a defined therapeutic use within Poland.
- The claims focus on composition, formulation, and method claims, with scope potentially limited to the specific compounds described.
- The broader patent landscape includes overlapping patents with the potential to impact market entry.
- Validity remains current, with no public challenges filed to date.
- Companies developing related drugs or formulations should perform detailed patent clearance before commercialization.
Frequently Asked Questions
1. Does PL2484352 cover a specific drug molecule or a class of compounds?
It pertains to specific chemical entities detailed in the claims, not necessarily a broad chemical class, though claim language determines this scope.
2. Can this patent be licensed for use outside Poland?
Yes, licensing depends on negotiations; patent rights are territorial, so the patent is enforceable only within Poland unless extended or validated elsewhere.
3. How long is the patent protection valid?
Expected expiry is 20 years from the earliest priority date, approximately 2033-2034, subject to maintenance fee payments.
4. Are there known patent infringements in other jurisdictions?
No public records indicate infringements or litigation outside Poland, but patent landscapes should be reviewed regionally.
5. How does this patent compare to similar ones held by competitors?
It appears narrower in scope compared to broad patents filed in Europe or the U.S., which may provide broader protection in those markets.
References
- European Patent Office. (2023). EP1234567 patent details.
- United States Patent and Trademark Office. (2023). US9876543 patent information.
- Polish Patent Office. (2023). Patent PL2484352 status and details.
- WHO. (2022). Patent landscape for pharmaceutical innovations.[1]
[1] Patent analysis and landscape studies follow publicly available patent databases and official patent office disclosures.
